ATC Group: N05CD06 Lormetazepam

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05CD06 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05C Hypnotics and sedatives
4 N05CD Benzodiazepine derivatives
5 N05CD06 Lormetazepam

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 mg

Active ingredients in N05CD06

Active Ingredient Description
Lormetazepam

Lormetazepam is a benzodiazepine with anxiolytic, muscle relaxant, sedative and hypnotic properties. Clinical studies have shown minimal effects on REM sleep and on psychomotor performance on the day after treatment with lormetazepam. Lormetazepam is indicated for the short term treatment of insomnia.

Related product monographs

Title Information Source Document Type  
SEDALOR Solution for injection / infusion MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Cyprus (CY)

Germany (DE)

Japan (JP)

Malta (MT)

New Zealand (NZ)

Poland (PL)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.